- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03204786
Intranasal Vasopressin Treatment in Children With Autism
March 19, 2024 updated by: Antonio Hardan, Stanford University
The purpose of this clinical trial is to investigate the effectiveness of vasopressin nasal spray for treating symptoms associated with autism.
Vasopressin is a hormone that is produced naturally within the body and has been implicated in regulating social behaviors.
It has been proposed that administration of the hormone may also help improve social functioning in individuals with autism.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
108
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Briana Hernandez
- Phone Number: (650) 736-1235
- Email: avpclinicaltrial@stanford.edu
Study Contact Backup
- Name: Esha Dhawan
- Phone Number: (650) 736-1235
- Email: edhawan@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94305-5719
- Stanford University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 15 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Medically healthy outpatients between 6 and 17 years of age;
- Diagnostic and Statistical Manual 5th edition (DSM-5) criteria for Autism Spectrum Disorder (ASD) on the basis of clinical evaluation, confirmed with the Autism Diagnostic Interview Revised (ADI-R) and Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) or Childhood Autism Rating Scale, Second Edition (CARS-2);
- males and females;
- intelligence quotient (IQ) of 40 and above;
- rating of 4 or higher on the Social Communication domain of the Clinical Global Impressions Severity (CGI-S);
- Social Responsiveness Scale-2 Total Score of 70 and above;
- care provider who can reliably bring participant to clinic visits, provide trustworthy ratings, and interacts with participant on a regular basis;
- stable concomitant psychotropic medications or medications potentially affecting vasopressin for at least 4 weeks (with the exception of fluoxetine, 6 weeks);
- no planned changes in psychosocial and biomedical interventions during the trial;
- willingness to provide blood samples and ability to participate in key study procedures (i.e., diagnostic assessments and laboratory safety measurements).
Exclusion Criteria:
- DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder;
- regular nasal obstruction or nosebleeds;
- unstable medical conditions such as migraine, asthma attacks, or seizures, and significant physical illness (e.g. serious liver disease, renal dysfunction, or cardiac pathology);
- clinically significant abnormal electrocardiogram reading;
- history of hypersensitivity to vasopressin, its analogs, or compounding preservatives (e.g., chlorobutanol);
- evidence of a genetic mutation known to cause ASD or intellectual disability (e.g., Fragile X Syndrome); or metabolic, or infectious etiology for ASD on the basis of medical history, neurologic history, and available tests for inborn errors of metabolism and chromosomal analysis;
- significant hearing or vision impairments;
- habitually drinks large volumes of water;
- pregnant or sexually active females not using a reliable method of contraception;
- current use of any medications known to interact with vasopressin including: 1) carbamazepine (i.e., Tegretol); chlorpropamide; clofibrate; urea; fludrocortisone; tricyclic antidepressants (all of which may potentiate the antidiuretic effect of vasopressin when used concurrently); 2) demeclocycline; norepinephrine; lithium; heparin; alcohol (all of which may decrease the antidiuretic effect of vasopressin when used concurrently); 3) ganglionic blocking agents including benzohexonium, chlorisondamine, pentamine (all of which may produce a marked increase in sensitivity to the pressor effects of vasopressin);
- previous participation in a vasopressin clinical trial or current use of vasopressin;
- current use of desmopressin (DDAVP) or oxytocin.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vasopressin-Vasopressin
8 weeks of vasopressin nasal spray (16 international units twice daily)
|
Nasal Spray
|
Experimental: Placebo-Vasopressin
4 weeks of placebo nasal spray followed by 4 weeks of vasopressin nasal spray (16 international units twice daily)
|
Placebo Nasal Spray
Nasal Spray
|
Placebo Comparator: Placebo-Placebo
8 weeks of placebo nasal spray; followed by a 4 week open-label extension of vasopressin nasal spray (16 international units twice daily)
|
Placebo Nasal Spray
Nasal Spray
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) Total Scores during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Clinical Global Impression (CGI) scores during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on Reading the Mind in the Eyes Test (RMET) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on the Facial Emotion Recognition Test during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Repetitive Behavior Scale Revised (RBS-R) scores during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Spence Children's Anxiety Scale (SCAS) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on the Dosage Record Treatment Emergent Symptom Scale (DOTES) during treatment.
Time Frame: 2-week, 4-week; 6-week, 8-week
|
2-week, 4-week; 6-week, 8-week
|
Change from baseline in Overt Aggression Scale (OAS) during treatment.
Time Frame: 2-week, 4-week; 6-week, 8-week
|
2-week, 4-week; 6-week, 8-week
|
Baseline vasopressin concentration predicting primary and secondary behavioral outcome measures.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on vital signs (pulse) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on height during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on weight during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on electrocardiogram (EKG) P Duration during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on electrocardiogram (EKG) PR Interval during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on electrocardiogram (EKG) QRS Interval during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on electrocardiogram (EKG) QT Interval during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on blood clinical labs (Sodium) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on blood clinical labs (Potassium) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on blood clinical labs (Chloride) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on blood clinical labs (CO2) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on blood clinical labs (Anion Gap) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on blood clinical labs (Glucose) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on blood clinical labs (Creatinine) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on blood clinical labs (Urea Nitrogen) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on blood clinical labs (Calcium) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on blood clinical labs (Osmolality) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on urine clinical labs (Osmolality) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on vital signs (systolic blood pressure) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on vital signs (diastolic blood pressure) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Vineland Adaptive Behavior Scales, Third Edition (VABS-3) - Social Skills and Relationships Domain during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Pediatric Quality of Life (PedsQL) inventory scores during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on Eye Gaze Assessment (eye tracking) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on the Developmental Neuropsychological Assessment, Second Edition (NEPSY-II) Theory of Mind Test during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline the Diagnostic Analysis of Nonverbal Accuracy, Second Edition (DANVA-2) Child Voices Prosody Test during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Stanford Social Motivation Scale (also known as the Stanford Social Dimensional Scale) total scores during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in Parent Rated Anxiety Scale - Autism Spectrum Disorder (PRAS-ASD) score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Child's Sleep Habits Questionnaire (CSHQ) Score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline on spectral power in the alpha, theta, and gamma frequencies as measured by electroencephalogram (EEG) during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) Social Avoidance Factor Score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) Emotion Recognition Factor Score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) Interpersonal Relatedness Factor Score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) Insistence On Sameness Factor Score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) Repetitive Mannerisms Factor Score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) Attachment and Affiliation Factor Score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) Non-facial Communication Production Factor Score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) Facial Communication Production Factor Score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) Mental States Understanding Factor Score during treatment.
Time Frame: 4-week; 8-week
|
4-week; 8-week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Antonio Y. Hardan, M.D., Stanford University
- Principal Investigator: Karen J. Parker, Ph.D., Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 20, 2018
Primary Completion (Actual)
March 18, 2024
Study Completion (Actual)
March 18, 2024
Study Registration Dates
First Submitted
June 28, 2017
First Submitted That Met QC Criteria
June 28, 2017
First Posted (Actual)
July 2, 2017
Study Record Updates
Last Update Posted (Actual)
March 21, 2024
Last Update Submitted That Met QC Criteria
March 19, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-39972
- 1R01HD091972 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
National Database for Autism Research (NDAR) Submission per NIH requirements
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
National Taiwan University HospitalCompletedAutism Spectrum Disorder High-FunctioningTaiwan
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States